

The incidence and risk factors associated with varicella zoster virus infection in kidney transplant recipients after 1-month acyclovir prophylaxis in a CMV preemptive therapy era

Haein Kim,¹ Joo Hee Jung,² Min Jae Kim,¹ Hyosang Kim,³ Sung Shin,² Yong Pil Chong,¹ Young-Hoon Kim,² Sang-Oh Lee,¹ Sang-Ho Choi,¹ Yang Soo Kim,¹ Jun Hee Woo,¹ Su-Kil Park,³ Duck Jong Han², Sung-Han Kim^{1*}

Session Title: Infections in Immunocompromised Individuals Submission ID: 908383 Presentation date: Wednesday, October 21, 2020

Background

- Varicella zoster virus (VZV) infection is a well-known opportunistic infection in solid organ transplant recipients (SOT).
- Since the various strategies of the use of anti-herpetic drugs including ganciclovir or acyclovir have evolved, the epidemiology of VZV infection is changing. However, there are limited data on the recent incidence and risk factors of post-transplant VZV infection in popular preemptive ganciclovir era for CMV infection.
- We evaluated the incidence, risk factors and clinical characteristic of patients with development of post-transplant VZV infection in kidney transplant (KT) recipients after 1-month acyclovir prophylaxis in the hospital that adopted preemptive ganciclovir therapy for CMV infection

Methods

Study population

All patients admitted for KT in a kidney transplant unit between January 2014 and December 2017 at a 2,700 bed, tertiary-care hospital in Seoul, South Korea, were retrospectively reviewed. The resulting cohort was observed until November 2019 with a focus on VZV infection development after KT.

Study design and VZV, CMV and BKV prevention strategies

The objective of this study was to evaluate the incidence, risk factors and clinical characteristics of patients with development of post-transplant VZV infection in KT recipients. We administered a 1-month course of acyclovir prophylaxis therapy immediately after KT to all CMV seropositive recipients. In addition, our hospital adopted preemptive ganciclovir therapy for CMV infection in CMV seropositive KT recipients

Induction Immunosuppressive regimens

Anti-interleukin (IL)-2 receptor antibody (basiliximab, Simulect, Novartis, East Hanover, New Jersey, USA) or anti-thymocyte globulin (ATG) (Thymoglobulin, Genzyme/Sanofi Cambridge, Massachusetts, USA) were administered for induction therapy after KT. In simultaneous pancreas-kidney transplantation (SPK), ATG was administered for induction therapy. In addition, the KT recipients with ABO incompatible were administered rituximab (500 mg, 7-10 days before transplantation, Mabthera, Roche, Basel, Switzerland). Furthermore, the KT recipients with HLA cross-matching positivity underwent plasmapheresis until the anti-A or anti-B titer was < 1:8.


Assessment of outcomes

The primary outcome was development of VZV infection after KT. The development of VZV infection after transplantation was observed between January 2014 and November 2019. Secondary outcomes were mortality and rejection. Recipients were evaluated every month during the first 6 months after transplantation and every 3 months after that.

Departments of Infectious Diseases¹, Surgery,² and Nephrology,³ Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Patients' characteristics

(interquartile range [IQR], 31.2 to 55.3).



<u>Development of VZV infection</u>

95% CI 1.93 to 2.85).

years, 95% CI – 0.57 to 3.91, P = 0.14).

Table 1. Incidence of VZV infection in KT recipients

Variable	No. of patients	No. of V2 episodes		
Total patients with 1-month acyclovir prophylaxis	1288	107		
Living donor kidney transplantation	936	72		
Deceased donor kidney transplantation	277	31		
Pancreas-kidney transplantation	75	4		

1.47^b

0.40-3.77

271.89

ACV prophylaxis during CMV preemptive strategy, especially in those who was over 60 years or received deceased donor KT.



Contact Information

: Sung-Han Kim, MD, PhD **Department of Infectious Diseases** Asan Medical Center University of Ulsan College of Medicine E-mail: kimsunghanmd@hotmail.com

Risk factors of VZV infection

In a multivariate analysis, Age over 60 to 2.92, P = 0.03) and deceased donor kidney transplantation (HR 1.73, 95% CI 1.12 to 2.67, P = 0.01) were independent significant risk factors associated with development of VZV infection after KT. Re-transplantation (HR 0.35, 95% CI 0.11 to 1.09, P = 0.07), ganciclovir or valganciclovir treatment (HR 0.06, 95% CI 0.01 to 0.46, P = 0.01) and BK viremia episodes (HR 0.69, 95% CI 0.45 to 1.08, P = 0.11) showed a trend towards lower development of VZV infection in KT. Table 3. Univariate and multivariate analyses of risk factors for development of VZV infection

Variable	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Median age, years				
< 60 years	Reference			
\geq 60 years	1.64 (0.99-2.70)	0.05	1.77 (1.07-2.92)	0.03
Gender				
Male	Reference			
Female	1.10 (0.74-1.64)	0.63		
Primary reason for transplantation				
Glomerulonephritis	0.79 (0.51-1.22)	0.29		
Hypertension	1.00 (0.60-1.69)	0.99		
Diabetes mellitus	0.86 (0.54-1.38)	0.53		
Unknown	1.27 (0.81-1.98)	0.30		
Polycystic kidney disease	2.08 (0.96-4.48)	0.06		
Others	0.05 (0-NA)	0.81		
Fransplantation type				
Living donor kidney	0.76 (0.50-1.15)	0.19		
Deceased donor kidney	1.51 (0.98-2.33)	0.06	1.73 (1.12-2.67)	0.01
Pancreas and kidney	0.67 (0.25-1.81)	0.42		
Re-transplantation	0.36 (0.12-1.14)	0.08	0.35 (0.11-1.09)	0.07
ABO-mismatch transplantation	0.66 (0.38-1.14)	0.13		
HLA mismatch				
0	Reference			
1	0.64 (0.18-2.24)	0.48		
2	0.99 (0.49-2.02)	0.995		
3	0.71 (0.35-1.41)	0.33		
4	0.85 (0.40-1.79)	0.67		
5	0.78 (0.37-1.62)	0.50		
6	0.84 (0.39-1.80)	0.65		
Induction therapy at transplantation				
Anti-IL-2 receptor antibodies	0.82 (0.48-1.38)	0.45		
Anti-thymocyte antibodies	1.09 (0.61-1.95)	0.77		
Rituximab	0.68 (0.41-1.12)	0.13		
Rejection before VZV	0.66 (0.36-1.20)	0.17		
Within 3 months	1.35 (0.63-2.91)	0.17		
From 3 to 6 months	1.83 (0.58-5.77)	0.44		
From 6 to 12 months	1.26 (0.40-4.02)	0.30		
After 12 months	0.60 (0.24-1.47)	0.08		
Rejection treatment	0.00 (0.27 1.77)	0.20		
Steroid pulse therapy	1.10 (0.65-1.86)	0.71		
Therapeutic plasma exchange	1.54 (0.84-2.82)	0.16		
Rituximab	1.02 (0.45-2.32)	0.10		
Intravenous immunoglobulin	1.69 (0.74-3.85)	0.97		
Bortezomib	1.97 (0.62-6.20)	0.21		
Anti-thymocyte globulin	1.78 (0.44-7.22)	0.23		
CMV infection before VZV	0.77 (0.52-1.34)	0.42 0.19		
CMV disease before VZV	1.07 (0.40-2.92)	0.19		
				0.01
Ganciclovir or Valganciclovir treatment before VZV	0.07 (0.01-0.49)	0.01	0.06 (0.01-0.46)	0.01
3K viremia before VZV	0.63 (0.41-0.99)	0.04	0.69 (0.45-1.08)	0.11